Multiple myeloma is a hematological cancer of plasma B cells and remains incurable. Two major subtypes of myeloma, hyperdiploid MM (HMM) and non-hyperdiploid MM (NHMM), have distinct chromosomal alterations and different survival outcomes. Transcription factors (TrFs) have been implicated in myeloma oncogenesis, but their dysregulation in myeloma subtypes are less studied. Here, we developed a TrF-pathway coexpression analysis to identify altered coexpression between two sample types. We apply the method to the two myeloma subtypes and the cell cycle arrest pathway, which is significantly differentially expressed between the two subtypes. We find that TrFs MYC, nuclear factor-kB and HOXA9 have significantly lower coexpression with cell cycle arrest in HMM, co-occurring with their overactivation in HMM. In contrast, TrFs ESR1 (estrogen receptor 1), SP1 and E2F1 have significantly lower coexpression with cell cycle arrest in NHMM. SP1 chromatin immunoprecipitation targets are enriched by cell cycle arrest genes. These results motivate a cooperation model of ESR1 and SP1 in regulating cell cycle arrest, and a hypothesis that their overactivation in NHMM disrupts proper regulation of cell cycle arrest. Cotargeting ESR1 and SP1 shows a synergistic effect on inhibiting myeloma proliferation in NHMM cell lines. Therefore, studying TrF-pathway coexpression dysregulation in human cancers facilitates forming novel hypotheses toward clinical utility.
INTRODUCTION
Multiple myeloma (myeloma or MM) accounts for 10% of all hematological cancers. 1 It is a cancer of plasma B cells that undergoes monoclonal expansion in bone marrow, leading to symptoms such as kidney failures, frequent infections, anemia and bone fractures. The past decade has seen effective new treatment of MM such as proteasome inhibitors, but MM is still incurable, and the median survival time of myeloma patients is 7-8 years. 2 Chromosomal alterations revealed by cytogenetics and genomic techniques divide MMs into two major subtypes: hyperdiploid MM (HMM, 55-60% of MM) and non-hyperdiploid MM (NHMM, the rest of MM). HMM usually contains trisomies of chromosomes 3, 5, 7, 9, 11, 15, 19 and 21 and lacks translocation events, whereas NHMM is often associated with one-copy deletion of chromosome 13 and translocations involving the immunoglobulin heavy chain locus at 14q32, such as t(4;14), t (11;14) and t (14;16) . 2, 3 The survival outcome of HMM patients is better than that of NHMM. 2, 4 Therefore, it is of biological and clinical interest to ask whether and how the different genomic alteration profiles in the two subtypes contribute to MM pathogenesis and response to treatments.
Genome-wide gene expression profiling has contributed to the understanding of transcriptional alterations in myeloma and its subtypes compared with normal plasma B cells. Dysregulation of cell cycle-related genes, cyclin D1, D2 or D3 by translocation or hyperdiploidy, has been found to be a unifying and early pathogenic event in MM. 5, 6 Chng and co-workers 7, 8 have compared the gene expression between HMM and NHMM and found that HMM is associated with the activation of nuclear factor-kB (NF-kB), MYC and mitogen-activated protein kinase (MAPK) pathways, whereas the NHMM is associated with oncogeneactivating translocations. Agnelli and co-workers 9 have reported that differentially expressed genes and pathways between HMM and NHMM are mainly involved in protein biosynthesis, transcriptional machinery and oxidative phosphorylation. Most of these genes locate in the trisomy chromosomes of HMM and therefore could represent direct dosage effect of copy number gains. However, genomic alterations could also have indirect effect in gene expression through dysregulating transcription factors (TrFs) and members in signaling pathways. [10] [11] [12] In this project, we study how dysregulated TrFs in MM contribute to such indirect effect.
TrFs are the downstream effectors of signaling pathways within cells that receive growth and other signals from microenvironment. They also survey internal cellular homeostasis and make decisions on cell survival and proliferation. 13 Consequently, mutations in TrF genes or dysregulation of TrFs could have significant roles in cancer pathogenesis and drug resistance. In myeloma, overactivation of TrFs, such as NF-kB and MYC, is frequently observed and targeted as a potential therapy. 14, 15 Several approaches have been developed to infer TrF dysregulation from global gene expression profiles. Gene set enrichment analysis identifies the enrichment of the target genes of a TrF in differentially expressed genes between two biological conditions as indication for the TrF's own dysregulation. 16 Coexpression patterns between genes can also be analyzed to infer network changes between biological conditions. [17] [18] [19] [20] In this study, we hypothesize that between the HMM and NHMM myeloma subtypes, distinct TrF pathways dysregulate converging cancer pathways. This hypothesis motivates us to develop a TrF-pathway coexpression analysis method to identify TrFs that correlate with the cell cycle arrest pathway differently between the two subtypes. From this analysis, we find robust, subtype-specific coexpression patterns between TrFs and the cell cycle arrest pathway. These results support a novel cooperation model of ESR1 (estrogen receptor (ER) 1), SP1 and E2F1 on dysregulating cell cycle arrest in NHMM and their potential therapeutic implication. We then validate this prediction by drug combination treatments using four NHMM cell lines.
MATERIALS AND METHODS

Gene expression profiling data sets
We used the following public Gene Expression Omnibus data sets of myeloma gene expression profiling. GSE6477 (ref. 7) contains 70 expression samples of HMM and 70 samples of NHMM. GSE19784 (ref. 21) contains 201 samples with HMM status out of 320 samples. HMM and NHMM status are measured by fluorescence in situ hybridization in these two studies. Samples with ambiguous HMM status such as those with both fluorescence in situhybridization-measured trisomies and translocations were excluded from our analysis. GSE6365 (ref. 22 ) has 90 samples without information of HMM status. We applied a K-nearestneighbors-based method to classify samples into HMM and NHMM by their expression profiles. 23 The accuracy of this method is 485% when compared with fluorescence in situ hybridization-and copy number microarray-based HMM status. All the data sets were normalized and processed by the robust multiarray average method of Bioconductor to obtain expression values.
We used a TrF list containing nearly 200 common TrFs, 24 which is downloaded from the UCSC Genome Browser database.
The TrF-pathway coexpression algorithm
Paired t-test and correlation calculation. Paired t-test was used to compare the overall expression change of cancer-related pathways between the two subtypes of myeloma ( Figure 1a ). Each pathway gene has a pair of average expression value across the samples in the two subtypes, and the test assesses the overall expression difference of pathway genes between the two subtypes of myeloma.
Next, we apply Spearman's rank correlation to calculate the correlation coefficient between TrF and each pathway's genes in the HMM and NHMM subtypes, respectively ( Figure 1b ). Defined as Pearson's correlation between rank-transformed values, Spearman's correlation can detect nonlinear correlation and reduce bias caused by outlier samples.
Define Pattern Score to quantify TrF-pathway coexpression changes. In the next step, we have developed a formula to measure the change of TrF-pathway correlation pattern between the two myeloma subtypes. In the coexpression plot between a TrF and pathway genes (Figures 2a and b) , the x value and y value of each point represents the coexpression coefficient of a TrF and a gene in HMM and NHMM, respectively, rather than expression levels. Our analysis compares the coexpression alteration between the two subtypes.
We then define a score for the scatterplot pattern based on individual pathway genes (x, y) as:
Pattern Score ¼ Sum of all blue points (Distance between (x, y) and the diagonal line Â sign(|y| À |x|)) Â À log(P-value of Hotelling test).
The Hotelling P-value tests whether the correlation coefficients between the TrF and the pathway genes (blue points in Figure 2a ) are differently distributed compared with the correlation coefficients between the TrF and all the other genes (black points). Hotelling's T 2 test is a multivariate version of the t-test 25 and tests for the difference between the multivariate means of two populations. A significant P-value suggests that the TrF has a different functional relationship with this pathway compared with all other genes. The distance to the diagonal line of a point measures its degree of correlation coefficient change between the two subtypes, whereas the sign indicates in which subtype the point has higher absolute correlation with the TrF. For example, a gene point (x, y) in region A or B of Figure 2c has |y|4|x|, so this gene has higher absolute correlation with the TrF in NHMM (the Y axis subtype) than in HMM (the X axis subtype).
Pattern Score has larger absolute value when the scatterplot deviates from y ¼ x (Figures 2e and f) than when it is close to y ¼ x ( Figure 2d ). The significance of the Pattern Score is determined by permuting the subtype labels of the samples and comparing the observed Pattern Score to the distribution of the maximal score obtained from 1000 permutations (in the Bayesian model below we performed 100 permutations).
Linear regression to test the coexpression scatterplot's deviation from y ¼ x. A typical coexpression plot between a TrF and pathway genes is shown in Figure 2a , where blue points (pathway genes) and black points (the rest genes) represent the correlation coefficient between a specific TrF and a gene in HMM subtype (X axis) and NHMM subtype (Y axis). To detect the overall change of TrF-pathway coexpression between HMM and NHMM, we also checked whether or not the slope is 1 for the blue points (pathway genes) in Figure 2a . If the slope is significantly different from 1, it indicates that the coexpression of TrF and pathway genes has a global change between the two subtypes of myeloma. We rotated the coordinates of all points by 451 clockwise and then tested whether the regression slope in the new scatterplot is 0. A significant P-value indicates the change of TrF-pathway coexpression between the two subtypes.
Bayesian meta-analysis of multiple data sets. In the meta-analysis step, we used a Bayesian method to pool information across multiple data sets and downweight the results specific to a single data set. 26 Briefly, in each data set we first computed the correlation coefficient r between a TrF and a pathway gene, and then converted r into a standard normal statistic using Fisher's r-to-z transformation, with associated variance determined by sample size. Next, a hierarchical Bayesian model was used to combine the z values from different data sets to arrive at the TrF-gene correlation coefficient pooled across multiple data sets. We followed the formulas in Choi et al. 26 This meta-analysis was also performed on the null data generated from 100 permutations of sample group labels to assess the statistical significance of identified top TrFs.
Drug treatment, cell proliferation assay and isobologram analysis U266, MM1S and RPMI-8226 myeloma cells were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). OPM2 were obtained from the German collection of microorganisms and cell cultures (DSMZ, Braunschweig, Germany). The INA6 cell line was provided by Renate Burger (Leipzig, Germany). All the cell lines are NHMM-characterized subtype: INA-6 is a interleukin-6 (IL-6)-dependent human myeloma cell line, 27 whereas U266, OPM-2, RPMI-8226 and MM1S contain immunoglobulin locus translocation. 28, 29 The MM cell lines were cultured in RPMI 1640 supplemented with 10% fetal bovine serum. In the combination treatment experiments, cells were cultured with or without tamoxifen (TMX) in the absence or presence of terameprocol (TMP) for 48 h. MM cell proliferation was measured by DNA synthesis through [ 3 H]thymidine (Perkin-Elmer, Norwalk, CT, USA) incorporation assay, as described previously. 30 All experiments were carried out in triplicate.
The interaction between TMP and TMX was analyzed using the CalcuSyn software program (Biosoft, Ferguson, MO, USA), which is based on the Chou-Talalay method. 31 When combination index (CI) ¼ 1, it represents the conservation isobologram and indicates additive effects. CIo1 indicates synergism and CI41 indicates antagonism.
RESULTS
Motivations for studying the cell cycle arrest pathway and its coexpression with TrFs
Using the Chng data set 7 and major cancer pathways, 32, 33 we found that the cell cycle arrest pathway is significantly upregulated in HMM compared with NHMM ( Figure 1a ), and is upregulated in both subtypes compared with normal plasma cells. We also observed coexpression changes between TrFs and their target genes. For example, the coexpression pattern between a TrF SP1 and cyclin-dependent kinase CDK2, a transcriptional target of SP1, 34 is much stronger in HMM than in NHMM ( Figure 1b ).
The coexpression analysis can detect such changes that are not obvious from gene-wise differential expression analysis of either SP1 or CDK2 (P-value is 0.11 and 0.053, respectively). These results and existing knowledge of cell cycle's dysregulation in myeloma motivated us to develop a TrF-pathway coexpression analysis method to identify TrFs that differently correlate with the cell cycle arrest pathway between the two subtypes.
TrF-pathway differential coexpression analysis
We developed a statistical analysis method to detect coexpression changes between TrFs and genes in cancer-related pathways. Figure 1c outlines the analysis pipeline. Differentially expressed, cancer-related pathways between two biological conditions were first identified. We next scored TrFs that have significant coexpression changes with pathways of interest between two sample conditions. This method ranks TrFs by the degree of TrF-pathway coexpression changes between the two conditions. Finally, permutation of sample group labels was used to generate null data sets and call significantly TrFs.
We used this pipeline to ask what TrF's coexpression with the cell cycle arrest pathway has significant difference between the two myeloma subtypes, HMM and NHMM. The Pattern Score (defined in Materials and Methods) measures whether a TrF-pathway pair has an overall different correlation pattern between the two subtypes. If the pathway genes (blue points in Figure 2 ) and a TrF have largely unchanged coexpression between the two subtypes, the scatterplot of blue points centers along the diagonal line (y ¼ x) and the Pattern Score is close to zero (Figure 2d ). If the scatterplot has a slope far from 1, it indicates an overall change of TrF-pathway coexpression between the two subtypes and the Pattern Score will be much larger or smaller than 0 (Figures 2e and f) . We also used a linear regression to test whether the pattern has significant deviation from the diagonal line (see Materials and Methods). The P-value of this test is 0.896, o2.2e À 16 and 3.7e À 08 for the patterns in Overview of the TrF-pathway coexpression analysis. Using gene expression profiling data, we identify differentially expressed cancer pathways between two biological conditions. Next, we use a formula to score TrFs for their differential coexpression patterns with pathways of interest between the two conditions. Permutation of sample group labels was used to assess the statistical significance of top-ranked TrFs. Table 1 and Supplementary Table 2 list top-ranked TrFs that have significantly lower coexpression with cell cycle arrest genes in HMM compared with NHMM, including HOXA9, MYC and NF-kB family member c-Rel (REL). Also from Table 1 , CEBPB and STAT3 are involved in the IL-6 pathway, and NF-kB, MYC and ATF2 are involved in the MAPK signaling pathway. 35, 36 Both pathways promote myeloma initiation and progression. 2 Furthermore, RELA (p65, an NF-kB subunit, score ¼ À 138) and FOS (an IL-6 pathway member; score ¼ À 141) also have high scores, but their permutation P-values are not as significant. These two TrFs also associate with the MAPK signaling pathway and the IL-6 pathway. Our coexpression analysis arrived at findings consistent with the original study of GSE6477, which has reported that MYC, NF-kB, MAPK and IL-6 pathways are overexpressed in HMM than in NHMM. 7 Transcriptional dysregulation of cell cycle arrest in myeloma X Wang et al ESR1, SP1 and E2F1 have significantly lower coexpression with cell cycle arrest genes in NHMM In contrast to HMM, the transcriptional dysregulation in NHMM has been less studied, although the translocation events are more associated with NHMM. Table 2 and Supplementary Table 3 list topranked TrFs that have significantly lower coexpression with cell cycle arrest genes in NHMM compared with HMM. Among them, ESR1, SP1 and E2F1 are three TrFs known to influence cellular processes that include proliferation and apoptosis. [37] [38] [39] These results have not been reported by the original study of GSE6477. 7 Bayesian meta-analysis of multiple data sets improves the robustness of analysis We next asked whether these findings are specific to one data set (GSE6477) or general in myeloma. We added two other myeloma expression data sets that have both HMM and NHMM samples, GSE6365 (ref. 22 ) and GSE19784 (ref. 21) . We used a Bayesian hierarchical model to compute correlation coefficients between TrFs and genes by pooling across data sets and weighting their respective sample sizes. 26 The meta-analysis downweights TrF-pathway coexpression patterns specific to one data set, even if this pattern may be significant in the data set ( Figure 3a) , and enhances the patterns consistent across data sets but may not be significant in any one data set (Figure 3b ). Tables 3a and b lists the TrFs with significantly different coexpression with cell cycle arrest genes between HMM and NHMM after pooling the three data sets. Table 3b and Figure 3b show that both SP1 and ESR1 are still top-ranked as having significantly lower coexpression with cell cycle arrest genes in NHMM compared with HMM across different patient cohorts. Figure 3 . The coexpression patterns of TrFs AHR and ESR1 in individual data sets and in the meta-analysis. Meta-analysis averages out conflicting patterns in (a) and strengthens consistent patterns in (b). (a) The TrF AHR does not have a robust coexpression alteration between HMM and NHMM across the three individual data sets. The red and green dots represent two pathway genes and their correlation coefficients with the TrF. Because the coefficients of the same genes are quite different in the three data sets, the meta-analysis does not lead to a significant Pattern Score. (b) ESR1 has a robust coexpression alteration between HMM and NHMM across the three data sets. Most pathway genes such as those highlighted by the red and green dots remain at similar correlation coefficient positions in the three data sets, so the meta-analysis leads to a significant Pattern Score.
Cell cycle arrest genes are enriched by SP1 ChIP targets
Although coexpression analysis suggests regulatory role of SP1 on cell cycle arrest genes, it cannot determine whether such regulation is direct or indirect. We next analyzed SP1 ChIP-seq (chromatin immunoprecipitation followed by sequencing) data of GM12878, a lymphoblastoid cell line from the ENCODE project, to check if SP1 targets are enriched by cell cycle arrest pathway genes (http://hgdownload.cse.ucsc.edu/goldenPath/hg19/enco-deDCC/wgEncodeHaibTfbs). An enrichment supports a direct regulatory role of SP1 on the cell cycle arrest pathway. There are 2150 genes whose transcript starting site is within 3 kb upstream or downstream of the top 5000 SP1 peaks. Among the 310 cell cycle arrest genes we used in the coexpression analysis ( Supplementary Table 1 ), 85 have strong SP1 binding peaks near their transcript starting site regions (27%). Therefore, cell cycle arrest genes are enriched by SP1 targets (P-value ¼ 3.86e À 08) in this B-lymphocyte cell line. As myeloma cells come from the B-cell lineage, SP1 dysregulation is likely to directly affect the gene expression of cell cycle arrest pathway in myeloma.
We then analyzed an ESR1 ChIP-seq data in a breast cancer cell line MCF-7 (GSE25021), as ESR1 ChIP data are not available for B cells. There is no enrichment of ESR1 targets in cell cycle arrest genes. However, ESR is known to regulate genes indirectly through interactions with Sp1 TrF, 40 supporting its possible indirect regulation of the cell cycle arrest pathway.
A model of cooperation between SP1 and ESR1 on regulating cell cycle arrest
On the basis of these results and literature evidences, we proposed a model of cooperation between SP1 and ESR1 on regulating cell cycle arrest and their overactivation in NHMM (Figure 4 ). Overactivation of ESR1 in myeloma cells induces MAPK/ ERK pathways through c-SRC 41 (Step 1 in Figure 4 ), which in turn activate SP1, leading to increased expression of the downstream factor E2F1 (Step 2). Furthermore, both SP1 and ESR1 regulate cyclin D1 (CCND1), 42, 43 which is frequently abnormal in myeloma, 5 and lead to cell cycle progression (Step 3). This model suggests a combination therapy to inhibit both SP1 and ESR1 activities to overcome the limitations of single-drug treatments that inhibit either SP1 or ESR1 alone. For example, antiestrogen therapy, especially the most commonly used TMX, has major limitations including its partial agonist activity and constitutive or acquired resistance. 44 TMX resistance has been shown to be a result of increased ERa (product of ESR1) and Sp1 interaction that enhances the expression of E2F1. 45, 46 Synergistic growth inhibition effect of cotargeting SP1 and ESR1 in myeloma cells The cooperation model predicts an approach to preventing cell proliferation by intervening SP1 and ESR1's dysregulation in myeloma cells. We investigated the effect of cotargeting SP1 and ESR1 proteins on MM cell growth. Our recent work showed that Sp1 has a regulatory role in MM cell growth and survival, and it can be inhibited by the anti-MM activity of TMP, a small molecule that specifically competes with Sp1-DNA binding in vitro and in vivo. 30 In addition, TMX, an antagonist of ER, has been shown to induce growth arrest and apoptosis in MM cell lines. 37, 44 In our combination treatment experiments, NHMM cells were cultured for 48 h with TMX (0.5 and 20 mM), TMP (5 and 10 mM) or their combinations, and cell proliferation was measured by [ 3 H]thymidine uptake at 48 h. In four of the five cell lines treated, all combinations of TMX and TMP resulted in significant (P-value o0.05) and synergistic antiproliferative effect ( Figure 5 ), except the treatment with TMP (5 mM) and TMX (20 mM) for the OPM2 cell line. For example, treatment of TMX at 0.5 and 20 mM alone triggers 10% and 40% growth inhibition in U266 cells, respectively (Figure 5a ), which was further enhanced to 40% (CI ¼ 0.68) and 70% (CI ¼ 0.5) by combined treatment with TMP at 5 mM (Figure 5c , table rows in blue). In MM1S cells, a synergistic effect was achieved only at 72 h (data not shown).
DISCUSSION
This study starts from the two myeloma subtypes that have distinct and characteristic genomic alterations, which may have been selected during cancer cell evolution and lead to different paths to oncogenesis and differential survival outcomes. We hypothesize that the dysregulation of TrFs can induce coexpression alteration between a TrF and the genes it regulates Transcriptional dysregulation of cell cycle arrest in myeloma X Wang et al directly or indirectly. Because the cell cycle arrest pathway has significant expression level changes between the HMM and NHMM subtypes among cancer-related pathways, and that cell cycle dysregulation could be a common pathogenic mechanism in myeloma, 5 we have focused on the cell cycle arrest pathway.
We have developed a coexpression analysis method to identify TrF-pathway coexpression dysregulation in two major myeloma subtypes. Our analysis has revealed specific TrFs that could be dysregulated in each myeloma subtype, which in turn may lead to their reduced regulation of cell cycle arrest. On the basis of these results and literature evidences, we have proposed a cooperation model between TrFs SP1 and ESR1 in contributing to cell cycle dysregulation in myeloma. Our experiments show that combination treatment targeting both TrFs has synergistic effect on growth inhibition of myeloma cell lines, and therefore support the proposed model. Compared with the traditional method of differential expression analysis followed by gene set enrichment of pathways or TrF target sets, our coexpression method may identify TrFs whose targets are not differentially expressed but are differentially regulated by the TrFs, which are biologically relevant and complementary results to existing methods. In addition, the coexpression analysis can identify TrFs that dysregulate downstream genes in indirect ways, whereas TrF target enrichment analysis cannot. For example, using predicted TrF target information based on TRANSFAC, 24 we identified only a few TrFs, whose target genes are enriched in cell cycles arrest genes and which are also differentially expressed between HMM and NHMM in the GSE6477 data set, including MYC, MYB, CREB1, E2F3 and USF2 (Supplementary Table 4 ). This is in contrast to many TFs that we identified to differentially regulate cell cycle arrest genes between the two myeloma subtypes (Tables 1 and 2 ). In particular, our analysis identified ESR1's dysregulation in NHMM. ESR1 had been reported to regulate genes through indirect mechanisms such as by interacting with cofactors AP-1 and Sp1, 40 and our ChIP-seq analysis of ESR1 binding peaks showed no enrichment of cell cycle arrest genes. Finally, although TrF target enrichment analysis may suggest direct regulation, it is restricted to available target prediction or ChIP-seq data, whereas the coexpression does not require such information.
The TrF-pathway coexpression analysis has revealed dysregulated pathways that are consistent with previous analysis of HMM. Both our analysis and the original study of GSE6477 have found MYC and NF-kB pathways dysregulated in HMM. In addition, we have identified HOXA9 as the top TrF dysregulated in HMM because of its reduced coexpression with cell cycle arrest genes both in the GSE6477 data and in the Bayesian meta-analysis (Tables 1 and 3a) . Although HOXA9 was not identified in Chng et al., 7 it has recently been suggested as a candidate oncogene in myeloma by a genome-wide sequencing study. 47 HOXA9 is a TrFregulating gene expression, morphogenesis and differentiation. 48 A translocation event causing a fusion between HOXA9 and NUP98 has been associated with myeloid leukemogenesis. 49, 50 In MM, it has high expression level in patients lacking IgH translocations, 47 agreeing with that HOXA9 has a higher expression in HMM than in NHMM in the three data sets we analyzed (P-values of 0.076, 0.019 and 0.008). HOXA9-depleted cells show a competitive growth disadvantage, 47 suggesting its expression-related carcinogenesis role in myeloma. Therefore, HOXA9 with higher expression level in HMM is associated with oncogenesis, and co-occurring with our analysis, results of HOXA9s reduced coexpression with the cell cycle arrest pathway in HMM.
We have also identified TrFs SP1, ESR1 and E2F1 as having significantly lower coexpression with the cell cycle arrest pathway in NHMM compared with HMM (Tables 2 and 3b ). SP1 regulates a variety of processes such as cell growth, apoptosis, differentiation and immune responses. 38 It also mediates the transcription of cyclins and cyclin-dependent kinases. 43, 51 It has been recently shown to have an important regulatory role in MM cell growth and survival. 30 MM cells display increased SP1 protein (Sp1) nuclear levels and DNA binding activity compared with normal cells, and their interaction with bone marrow stromal cells lead to Sp1 activation via induction of the ERK signaling pathway. 30 Moreover, genetic inhibition of Sp1 with small interfering RNA and short hairpin RNA technologies and pharmacological inhibition with a specific Sp1 inhibitor significantly reduced MM cell growth and survival in vitro and in vivo. 30 ERs (ESR1 and ESR2) are nuclear receptors that are activated by the hormone estrogen and then bind to DNA to regulate downstream genes. 52 They are overexpressed in 70% of breast cancer samples, and these ER-positive cancers respond to ER antagonist such as TMX. 46, 53 Studies show that MM cells often express and overactivate ERs, and selective ER modulators induce G1-S cell cycle arrest and apoptosis in MM cells. 44, 54, 55 Moreover, ESR1 interacts with Sp1 to regulate transcription of downstream genes, including E2F1, a key regulator of the G1-S cell cycle checkpoint. 46, 56 Drug combination is widely used in treating cancers, helping achieve synergistic therapeutic effect and minimizing drug resistance. 31 On the basis of the TrF-pathway results and literature reviews, we have proposed a cooperation model of SP1 and ESR1's roles in regulating cell cycle arrest and their dysregulation in NHMM. A combination treatment targeting both SP1 and ESR1 has synergistic growth inhibition effect on NHMM cell lines. These result support the SP1-ESR1 cooperation model and point to further experimental follow-up.
There are areas for further improvement on this study. First, as myeloma is a cancer of bone marrow, no normal bone marrows are available in large numbers for comparative expression profiling. Owing to small sample size or lack of normal samples in the data sets used, we have not included normal samples in the analysis. In this study, we have used the evidence that TrFs such as MYC and HOXA9 are both overactivated in HMM and have lower coexpression with the cell cycle arrest pathway to associate a TrF's lower coexpression in a subtype with its dysregulation in the subtype. Comparing MM subtypes with normal samples in future studies using the coexpression analysis could help confirm this association. Comparing with normal samples can also reveal TrFs that are commonly dysregulated in both subtypes. The second limitation is the use of TrFs that are based on TRANSFAC TrFs, which are well studied. 57 Although this helps interpreting these TrFs' roles in cell cycle pathways and designing experimental validation, we may miss novel mechanisms involving TrFs not in the list. Expanding the analysis to predicted TrFs based on their DNA-binding domains will alleviate this limitation. 58 The third limitation is that when a TrF has significant coexpression with a gene in a pathway, relationship between the TrF and the gene may not be causal or direct. Other genetic regulators may regulate both the TrF and the gene, or the TrF regulates the gene via intermediate regulators. We have checked the ChIP-seq based gene targets of SP1 and found that they are enriched by cell cycle arrest genes. This lends support that SP1 directly regulates many cell cycle arrest genes, but wet experiments are needed to validate these predictions. Bioinformatic algorithms such as ARACNE may be used to better distinguish direct and indirect coexpression relationship. 59 These limitations point to areas to improve the TrFpathway coexpression analysis for better understanding of regulatory alterations in cancer. Another interesting direction is to use coexpression signatures as biomarker for patient prognosis. 60 The TrF-pathway coexpression analysis code is available at http://www.chenglilab.net.
